Skip to main content
SpringerLink
Log in

Neuro Ophthalmology and Oculoplasty

  • Chapter
  • First Online:
Oculoplastic Surgery

  • 1002 Accesses

Abstract

A variety of conditions may present with symptoms and signs that overlap between the subspecialties of oculoplastics and neuro-ophthalmology . Ideally, co-management of these conditions will be possible but in reality, these subspecialties are under-represented around the world and thus, this may not be feasible. This chapter provides an overview of the most common overlapping conditions and attempts to emphasize the most critical clinical and therapeutic considerations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Suggested Readings

  1. Smith SV, Lee AG. Update on ocular myasthenia gravis. Neurol Clin. 2017;35(1):115–23.

    Article  PubMed  Google Scholar 

  2. Jabbehdari S, Golnik KCJAoES. Myasthenia gravis. 2018. 2018;3(5).

    Google Scholar 

  3. Thanvi BR, Lo TC. Update on myasthenia gravis. Postgrad Med J. 2004;80(950):690–700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun. 2014;48–49:143–8.

    Article  CAS  PubMed  Google Scholar 

  5. Lee JI, Jander S. Myasthenia gravis: recent advances in immunopathology and therapy. Expert Rev Neurother. 2017;17(3):287–99.

    Article  CAS  PubMed  Google Scholar 

  6. Gwathmey KG, Burns TM. Myasthenia Gravis. Semin Neurol. 2015;35(4):327–39.

    Article  PubMed  Google Scholar 

  7. Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology. 1999;106(7):1282–6.

    Article  CAS  PubMed  Google Scholar 

  8. Peragallo JH, Bitrian E, Kupersmith MJ, Zimprich F, Whittaker TJ, Lee MS, et al. Relationship between age, gender, and race in patients presenting with myasthenia gravis with only ocular manifestations. J Neuroophthalmol. 2016;36(1):29–32.

    Article  PubMed  Google Scholar 

  9. Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013;12(9):918–23.

    Article  CAS  PubMed  Google Scholar 

  10. Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wolfe GI, Kaminski HJ, Sonnett JR, Aban IB, Kuo HC, Cutter GR. Randomized trial of thymectomy in myasthenia gravis. J Thorac Dis. 2016;8(12):E1782–3.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Uzawa A, Kawaguchi N, Kanai T, Himuro K, Oda F, Yoshida S, et al. Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. J Neurol. 2015;262(4):1019–23.

    Article  CAS  PubMed  Google Scholar 

  13. Liu Z, Lai Y, Yao S, Feng H, Zou J, Liu W, et al. Clinical outcomes of thymectomy in myasthenia gravis patients with a history of crisis. World J Surg. 2016;40(11):2681–7.

    Article  PubMed  Google Scholar 

  14. Kaufman AJ, Palatt J, Sivak M, Raimondi P, Lee DS, Wolf A, et al. Thymectomy for myasthenia gravis: complete stable remission and associated prognostic factors in over 1000 cases. Semin Thorac Cardiovasc Surg. 2016;28(2):561–8.

    Article  PubMed  Google Scholar 

  15. Benatar M, McDermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, et al. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve. 2016;53(3):363–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41(5):593–8.

    Article  CAS  PubMed  Google Scholar 

  18. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394–9.

    Article  CAS  Google Scholar 

  19. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400–6.

    Article  CAS  PubMed  Google Scholar 

  20. Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):970–7.

    Article  PubMed  Google Scholar 

  21. Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. 2012;12:CD005081.

    Google Scholar 

  22. Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78(3):367–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bentley CR, Dawson E, Lee JP. Active management in patients with ocular manifestations of myasthenia gravis. Eye (Lond). 2001;15(Pt 1):18–22.

    Article  CAS  Google Scholar 

  25. Brogan K, Farrugia ME, Crofts K. Ptosis surgery in patients with myasthenia gravis: a useful adjunct to medical therapy. Semin Ophthalmol. 2018;33(3):429–34.

    Article  PubMed  Google Scholar 

  26. Azhar SS, Tang RA, Dorotheo EU. Giant cell arteritis: diagnosing and treating inflammatory disease in older adults. Geriatrics. 2005;60(8):26–30.

    PubMed  Google Scholar 

  27. Rahman W, Rahman FZ. Giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol. 2005;50(5):415–28.

    Article  PubMed  Google Scholar 

  28. Salvarani C, Pipitone N, Versari A, Hunder GG. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol. 2012;8(9):509–21.

    Article  CAS  PubMed  Google Scholar 

  29. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42(2):311–7.

    Article  CAS  PubMed  Google Scholar 

  30. Brass SD, Durand ML, Stone JH, Chen JW, Stone JR. Case records of the Massachusetts general hospital. Case 36-2008. A 59-year-old man with chronic daily headache. N Engl J Med. 2008;359(21):2267–78.

    Google Scholar 

  31. Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113(10):1842–5.

    Article  PubMed  Google Scholar 

  32. Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41(6):866–71.

    Article  CAS  PubMed  Google Scholar 

  33. Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. 2004;14(3):245–57.

    Article  CAS  PubMed  Google Scholar 

  34. Riordan-Eva P, Landau K, O’Day J. Temporal artery biopsy in the management of giant cell arteritis with neuro-ophthalmic complications. Br J Ophthalmol. 2001;85(10):1248–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Nordborg E, Nordborg C. Giant cell arteritis: strategies in diagnosis and treatment. Curr Opin Rheumatol. 2004;16(1):25–30.

    Article  PubMed  Google Scholar 

  36. McDonnell PJ, Moore GW, Miller NR, Hutchins GM, Green WR. Temporal arteritis. A clinicopathologic study. Ophthalmology. 1986;93(4):518–30.

    Article  CAS  PubMed  Google Scholar 

  37. Sane M, Selvadurai A, Reidy J, Higgs D, Gonzalez-Fernandez F, Lincoff N. Transient visual loss due to reversible ‘pending’ central retinal artery occlusion in occult giant cell arteritis. Eye (Lond). 2014;28(11):1387–90.

    Article  CAS  Google Scholar 

  38. Chambers WA, Bernardino VBJJoN-O. Specimen length in temporal artery biopsies. 1988;8(2):121–6.

    Google Scholar 

  39. Goodman BW Jr. Temporal arteritis. Am J Med. 1979;67(5):839–52.

    Article  PubMed  Google Scholar 

  40. Clearkin LG. IV steroids for central retinal artery occlusion in giant-cell arteritis. Ophthalmology. 1992;99(10):1482–4.

    Article  CAS  PubMed  Google Scholar 

  41. Hayreh SS, Biousse V. Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids? J Neuroophthalmol. 2012;32(3):278–87.

    Article  PubMed  Google Scholar 

  42. Lessell S. Optic neuropathy in giant cell arteritis. J Neuroophthalmol. 2005;25(3):247.

    Article  PubMed  Google Scholar 

  43. Chan CC, Paine M, O’Day J. Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol. 2005;25(1):14–7.

    Article  PubMed  Google Scholar 

  44. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–28.

    Article  CAS  PubMed  Google Scholar 

  45. Conway R, O’Neill L, Gallagher P, McCarthy GM, Murphy CC, Veale DJ, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum. 2018;48(3):523–8.

    Article  CAS  PubMed  Google Scholar 

  46. Knyazer B, Smolar J, Lazar I, Rosenberg E, Tsumi E, Lifshitz T, et al. Iatrogenic horner syndrome: etiology, diagnosis and outcomes. Isr Med Assoc J. 2017;19(1):34–8.

    PubMed  Google Scholar 

  47. Jeffery AR, Ellis FJ, Repka MX, Buncic JR. Pediatric Horner syndrome. J AAPOS. 1998;2(3):159–67.

    Article  CAS  PubMed  Google Scholar 

  48. Martin TJ. Horner syndrome: a clinical review. ACS Chem Neurosci. 2018;9(2):177–86.

    Article  CAS  PubMed  Google Scholar 

  49. Bell RL, Atweh N, Ivy ME, Possenti P. Traumatic and iatrogenic Horner syndrome: case reports and review of the literature. J Trauma. 2001;51(2):400–4.

    Article  CAS  PubMed  Google Scholar 

  50. Sadaka A, Schockman SL, Golnik KC. Evaluation of Horner syndrome in the MRI Era. J Neuroophthalmol. 2017;37(3):268–72.

    Article  PubMed  Google Scholar 

  51. Martin TJ. Horner’s syndrome, Pseudo-Horner’s syndrome, and simple anisocoria. Curr Neurol Neurosci Rep. 2007;7(5):397–406.

    Article  CAS  PubMed  Google Scholar 

  52. Wilhelm H, Ochsner H, Kopycziok E, Trauzettel-Klosinski S, Schiefer U, Zrenner E. Horner’s syndrome: a retrospective analysis of 90 cases and recommendations for clinical handling. Ger J Ophthalmol. 1992;1(2):96–102.

    CAS  PubMed  Google Scholar 

  53. Kanagalingam S, Miller NR. Horner syndrome: clinical perspectives. Eye Brain. 2015;7:35–46.

    PubMed  PubMed Central  Google Scholar 

  54. Czarnecki JS, Pilley SF, Thompson HS. The analysis of anisocoria. The use of photography in the clinical evaluation of unequal pupils. Can J Ophthalmol. 1979;14(4):297–302.

    Google Scholar 

  55. Yoo YJ, Yang HK, Hwang JM. Efficacy of digital pupillometry for diagnosis of Horner syndrome. PLoS ONE. 2017;12(6):e0178361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Al-Moosa A, Eggenberger E. Neuroimaging yield in isolated Horner syndrome. Curr Opin Ophthalmol. 2011;22(6):468–71.

    Article  PubMed  Google Scholar 

  57. Chen Y, Morgan ML, Barros Palau AE, Yalamanchili S, Lee AG. Evaluation and neuroimaging of the Horner syndrome. Can J Ophthalmol. 2015;50(2):107–11.

    Article  PubMed  Google Scholar 

  58. Lee JH, Lee HK, Lee DH, Choi CG, Kim SJ, Suh DC. Neuroimaging strategies for three types of Horner syndrome with emphasis on anatomic location. AJR Am J Roentgenol. 2007;188(1):W74–81.

    Article  PubMed  Google Scholar 

  59. George A, Haydar AA, Adams WM. Imaging of Horner’s syndrome. Clin Radiol. 2008;63(5):499–505.

    Article  CAS  PubMed  Google Scholar 

  60. Davagnanam I, Fraser CL, Miszkiel K, Daniel CS, Plant GT. Adult Horner’s syndrome: a combined clinical, pharmacological, and imaging algorithm. Eye (Lond). 2013;27(3):291–8.

    Article  CAS  Google Scholar 

  61. Beebe JD, Kardon RH, Thurtell MJ. The yield of diagnostic imaging in patients with isolated horner syndrome. Neurol Clin. 2017;35(1):145–51.

    Article  PubMed  Google Scholar 

  62. Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin. 2014;32(2):363–96.

    Article  PubMed  Google Scholar 

  63. Wall M, White WN 2nd. Asymmetric papilledema in idiopathic intracranial hypertension: prospective interocular comparison of sensory visual function. Invest Ophthalmol Vis Sci. 1998;39(1):134–42.

    CAS  PubMed  Google Scholar 

  64. Frisen L. Swelling of the optic nerve head: a backstage view of a staging scheme. J Neuroophthalmol. 2017;37(1):3–6.

    Article  PubMed  Google Scholar 

  65. Kesler A, Goldhammer Y, Hadayer A, Pianka P. The outcome of pseudotumor cerebri induced by tetracycline therapy. Acta Neurol Scand. 2004;110(6):408–11.

    Article  CAS  PubMed  Google Scholar 

  66. Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis. 1995;55(3):165–8.

    CAS  PubMed  Google Scholar 

  67. Caruana DM, Wylie G. ‘Washout’ period for oral tetracycline antibiotics prior to systemic isotretinoin. Br J Dermatol. 2016;174(4):929–30.

    Article  CAS  PubMed  Google Scholar 

  68. Fraser JA, Bruce BB, Rucker J, Fraser LA, Atkins EJ, Newman NJ, et al. Risk factors for idiopathic intracranial hypertension in men: a case-control study. J Neurol Sci. 2010;290(1–2):86–9.

    Article  PubMed  Google Scholar 

  69. Wardly D, Wolford LM, Veerappan V. Idiopathic intracranial hypertension eliminated by counterclockwise maxillomandibular advancement: a case report. Cranio. 2017;35(4):259–67.

    Article  PubMed  Google Scholar 

  70. Henry M, Driscoll MC, Miller M, Chang T, Minniti CP. Pseudotumor cerebri in children with sickle cell disease: a case series. Pediatrics. 2004;113(3 Pt 1):e265–9.

    Article  PubMed  Google Scholar 

  71. van Gelder T, van Gemert HM, Tjiong HL. A patient with megaloblastic anaemia and idiopathic intracranial hypertension. Case history. Clin Neurol Neurosurg. 1991;93(4):321–2.

    Article  PubMed  Google Scholar 

  72. Tugal O, Jacobson R, Berezin S, Foreman S, Berezin S, Brudnicki A, et al. Recurrent benign intracranial hypertension due to iron deficiency anemia. Case report and review of the literature. Am J Pediatr Hematol Oncol. 1994;16(3):266–70.

    Google Scholar 

  73. Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2012;83(5):488–94.

    Article  PubMed  Google Scholar 

  74. Keltner JL. Optic nerve sheath decompression. How does it work? Has its time come? Arch Ophthalmol. 1988;106(10):1365–9.

    Google Scholar 

  75. Spoor TC, Ramocki JM, Madion MP, Wilkinson MJ. Treatment of pseudotumor cerebri by primary and secondary optic nerve sheath decompression. Am J Ophthalmol. 1991;112(2):177–85.

    Article  CAS  PubMed  Google Scholar 

  76. Flynn WJ, Westfall CT, Weisman JS. Transient blindness after optic nerve sheath fenestration. Am J Ophthalmol. 1994;117(5):678–9.

    Article  CAS  PubMed  Google Scholar 

  77. Huang LC, Winter TW, Herro AM, Rosa PR, Schiffman JC, Pasol J, et al. Ventriculoperitoneal shunt as a treatment of visual loss in idiopathic intracranial hypertension. J Neuroophthalmol. 2014;34(3):223–8.

    Article  PubMed  Google Scholar 

  78. Tarnaris A, Toma AK, Watkins LD, Kitchen ND. Is there a difference in outcomes of patients with idiopathic intracranial hypertension with the choice of cerebrospinal fluid diversion site: a single centre experience. Clin Neurol Neurosurg. 2011;113(6):477–9.

    Article  PubMed  Google Scholar 

  79. Abubaker K, Ali Z, Raza K, Bolger C, Rawluk D, O’Brien D. Idiopathic intracranial hypertension: lumboperitoneal shunts versus ventriculoperitoneal shunts–case series and literature review. Br J Neurosurg. 2011;25(1):94–9.

    Article  PubMed  Google Scholar 

  80. Farb RI, Vanek I, Scott JN, Mikulis DJ, Willinsky RA, Tomlinson G, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003;60(9):1418–24.

    Article  CAS  PubMed  Google Scholar 

  81. Radvany MG, Solomon D, Nijjar S, Subramanian PS, Miller NR, Rigamonti D, et al. Visual and neurological outcomes following endovascular stenting for pseudotumor cerebri associated with transverse sinus stenosis. J Neuroophthalmol. 2013;33(2):117–22.

    Article  PubMed  Google Scholar 

  82. Purvin VA, Trobe JD, Kosmorsky G. Neuro-ophthalmic features of cerebral venous obstruction. Arch Neurol. 1995;52(9):880–5.

    Article  CAS  PubMed  Google Scholar 

  83. Bono F, Giliberto C, Mastrandrea C, Cristiano D, Lavano A, Fera F, et al. Transverse sinus stenoses persist after normalization of the CSF pressure in IIH. Neurology. 2005;65(7):1090–3.

    Article  CAS  PubMed  Google Scholar 

  84. Ahmed RM, Wilkinson M, Parker GD, Thurtell MJ, Macdonald J, McCluskey PJ, et al. Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions. AJNR Am J Neuroradiol. 2011;32(8):1408–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Ahmed R, Friedman DI, Halmagyi GM. Stenting of the transverse sinuses in idiopathic intracranial hypertension. J Neuroophthalmol. 2011;31(4):374–80.

    Article  PubMed  Google Scholar 

  86. Shemesh A, Margolin E. Kearns Sayre syndrome. Treasure Island (FL): StatPearls; 2018.

    Google Scholar 

  87. McClelland C, Manousakis G, Lee MS. Progressive external ophthalmoplegia. Curr Neurol Neurosci Rep. 2016;16(6):53.

    Article  PubMed  Google Scholar 

  88. Bucelli RC, Lee MS, McClelland CM. Chronic progressive external ophthalmoplegia in the absence of ptosis. J Neuroophthalmol. 2016;36(3):270–4.

    Article  PubMed  Google Scholar 

  89. Ahn J, Kim NJ, Choung HK, Hwang SW, Sung M, Lee MJ, et al. Frontalis sling operation using silicone rod for the correction of ptosis in chronic progressive external ophthalmoplegia. Br J Ophthalmol. 2008;92(12):1685–8.

    Article  CAS  PubMed  Google Scholar 

  90. Richardson C, Smith T, Schaefer A, Turnbull D, Griffiths P. Ocular motility findings in chronic progressive external ophthalmoplegia. Eye (Lond). 2005;19(3):258–63.

    Article  CAS  Google Scholar 

  91. Mullie MA, Harding AE, Petty RK, Ikeda H, Morgan-Hughes JA, Sanders MD. The retinal manifestations of mitochondrial myopathy. A study of 22 cases. Arch Ophthalmol. 1985;103(12):1825–30.

    Google Scholar 

  92. Ota Y, Miyake Y, Awaya S, Kumagai T, Tanaka M, Ozawa T. Early retinal involvement in mitochondrial myopathy with mitochondrial DNA deletion. Retina. 1994;14(3):270–6.

    Article  CAS  PubMed  Google Scholar 

  93. Meire F, De Laey JJ, de Bie S, van Staey M, Matton MT. Dominant optic nerve atrophy with progressive hearing loss and chronic progressive external ophthalmoplegia (CPEO). Ophthalmic Paediatr Genet. 1985;5(1–2):91–7.

    Article  CAS  PubMed  Google Scholar 

  94. Gonzalez-Moron D, Bueri J, Kauffman MA. Progressive external ophthalmoplegia (PEO) due to a mutation in the C10orf2 (PEO1) gene mimicking a myasthenic crisis. BMJ Case Rep. 2013;2013.

    Google Scholar 

  95. Behbehani R, Sharfuddin K, Anim JT. Mitochondrial ophthalmoplegia with fatigable weakness and elevated acetylcholine receptor antibody. J Neuroophthalmol. 2007;27(1):41–4.

    Article  PubMed  Google Scholar 

  96. Miller NR WF, Hoyt WF. Walsh and Hoyt’s clinical neuro-ophthalmology, 6th ed. Philadelphia, PA, London: Lippincott Williams & Wilkins; 2005.

    Google Scholar 

  97. Lapid O, Lapid-Gortzak R, Barr J, Rosenberg L. Eyelid crutches for ptosis: a forgotten solution. Plast Reconstr Surg. 2000;106(5):1213–4.

    Article  CAS  PubMed  Google Scholar 

  98. de Castro FA, Cruz AA, Sobreira CF. Brow motility in mitochondrial myopathy. Ophthalmic Plast Reconstr Surg. 2010;26(6):416–9.

    Article  PubMed  Google Scholar 

  99. Wallace DK, Sprunger DT, Helveston EM, Ellis FD. Surgical management of strabismus associated with chronic progressive external ophthalmoplegia. Ophthalmology. 1997;104(4):695–700.

    Article  CAS  PubMed  Google Scholar 

  100. Tinley C, Dawson E, Lee J. The management of strabismus in patients with chronic progressive external ophthalmoplegia. Strabismus. 2010;18(2):41–7.

    Article  PubMed  Google Scholar 

  101. Chaudhry IA, Elkhamry SM, Al-Rashed W, Bosley TM. Carotid cavernous fistula: ophthalmological implications. Middle East Afr J Ophthalmol. 2009;16(2):57–63.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Barrow DL, Spector RH, Braun IF, Landman JA, Tindall SC, Tindall GT. Classification and treatment of spontaneous carotid-cavernous sinus fistulas. J Neurosurg. 1985;62(2):248–56.

    Article  CAS  PubMed  Google Scholar 

  103. Zhu L, Liu B, Zhong J. Post-traumatic right carotid-cavernous fistula resulting in symptoms in the contralateral eye: a case report and literature review. BMC Ophthalmol. 2018;18(1):183.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Fattahi TT, Brandt MT, Jenkins WS, Steinberg B. Traumatic carotid-cavernous fistula: pathophysiology and treatment. J Craniofac Surg. 2003;14(2):240–6.

    Article  PubMed  Google Scholar 

  105. Ellis JA, Goldstein H, Connolly ES Jr, Meyers PM. Carotid-cavernous fistulas. Neurosurg Focus. 2012;32(5):E9.

    Article  PubMed  Google Scholar 

  106. Gupta AK, Purkayastha S, Krishnamoorthy T, Bodhey NK, Kapilamoorthy TR, Kesavadas C, et al. Endovascular treatment of direct carotid cavernous fistulae: a pictorial review. Neuroradiology. 2006;48(11):831–9.

    Article  PubMed  Google Scholar 

  107. Badilla J, Haw C, Rootman J. Superior ophthalmic vein cannulation through a lateral orbitotomy for embolization of a cavernous dural fistula. Arch Ophthalmol. 2007;125(12):1700–2.

    Article  PubMed  Google Scholar 

  108. Goldberg RA, Goldey SH, Duckwiler G, Vinuela F. Management of cavernous sinus-dural fistulas. Indications and techniques for primary embolization via the superior ophthalmic vein. Arch Ophthalmol. 1996;114(6):707–14.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Illinois, USA

    Sayena Jabbehdari

  2. Department of Ophthalmology, University of Cincinnati Medical Center, CARE/Crawley Building, Suite E-870, 3235 Eden Avenue, Cincinnati, 45267, OH, USA

    Karl C. Golnik

  3. Cincinnati Eye Institute, Cincinnati, OH, USA

    Karl C. Golnik

Authors
  1. Sayena Jabbehdari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl C. Golnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl C. Golnik .

Editor information

Editors and Affiliations

  1. Cairo University, Dokki, Cario, Egypt

    Essam A. El Toukhy

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jabbehdari, S., Golnik, K.C. (2020). Neuro Ophthalmology and Oculoplasty. In: El Toukhy, E. (eds) Oculoplastic Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-36934-7_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-36934-7_30

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-36933-0

  • Online ISBN: 978-3-030-36934-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation